We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App





New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015

By LabMedica International staff writers
Posted on 28 Jul 2015
Print article
The PreludeLX-4MD, a four-channel HPLC that quadruples clinical throughput capabilities by performing up to 4 parallel LC-MS separations simultaneously in a single instrument.
The PreludeLX-4MD, a four-channel HPLC that quadruples clinical throughput capabilities by performing up to 4 parallel LC-MS separations simultaneously in a single instrument. (Photo courtesy of Thermo Fisher Scientific)
A new Class-I, four-channel HPLC that enables labs to increase efficiency by performing multiple parallel LC-MS separations simultaneously in a single instrument, is being exhibited at the AACC 2015 Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA) in Booth 3135.

Thermo Fisher Scientific Inc. (Waltham, MA, USA) now offers its new Prelude LX-4 MD HPLC, listed with the FDA as a Class I medical device for general clinical use. Prelude LX-4 MD HPLC quadruples the productivity of a single-channel HPLC by using four parallel channels to deliver up to 4 separations in a single instrument, streamlining LC-MS workflows, reducing mass spectrometer idle time, and keeping free valuable bench space. The four channels can run identical or different LC-MS assays simultaneously, providing flexibility for varying clinical separations and maximizing mass spectrometer utilization.

"We are strongly committed to bringing the advantages of LC-MS to the clinical market,” said Bradley Hart, Thermo Fisher Scientific, “The Prelude LX-4 MD is one of the first products within a broader initiative to make sample separations and mass spectrometry more useful and accessible to the clinician.”

Prelude LX-4 MD is the newest addition to the family of Thermo Scientific chromatography and mass spectrometry instruments and software for the clinical lab, which includes the Endura MD triple quadrupole mass spectrometer, Prelude MD HPLC, and software ClinQuan MD.

Related Links:

Thermo Fisher Scientific
Thermo Scientific Clinical Diagnostics
American Association for Clinical Chemistry (AACC)


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.